greeksoup/ stocks
Stocks / United States / CAH · Wholesale-Drugs, Proprietaries & Druggists' Sundries · NYSE

Cardinal Health Inc. (CAH)

Compare with another name

Cardinal Health Inc. (CAH) reported revenue of $65.6 billion for Q2 FY2026, the quarter ended 31 December 2025, up 18.8% on the same quarter a year earlier. Net income was $467 million, up 16.8% on the year. The figures are the company's own, from the 10-Q it filed with the SEC on 5 February 2026.

Revenue$65.6 billionup 18.8%
Net income$467 millionup 16.8%
Diluted EPSn/a
QuarterQ2 FY2026ended 31 December 2025

Ratios

From the filings

ROEn/a
ROCEn/a
Operating margin1.0%
Net margin0.7%
FCF margin2.3%
Interest cover8.02
Debt to equityn/a
Cash conversion3.67
Share count, 1 year-2.6%
Sales CAGR, 3 years7.4%
Profit CAGR, 3 years73.2%
EPS, TTMn/a

At the close of 21 September 2026

Price$225.75
Market cap$53.1 billion
Stock P/E32.54
Price to bookn/a
EV / EBITDA17.18
Dividend yield0.9%
Market cap / sales0.22
52-week high$248.61
52-week low$147.47
Price, 1 year50.9%
Price CAGR, 3 years36.4%
Price CAGR, 5 years34.6%

Every figure is arithmetic on the filed lines (hover a name for the formula); the priced ones use the latest daily close, CBOE delayed quotes, daily history, by CBOE, for splits. Debt to equity here stands on the one borrowings figure Cardinal Health Inc. files, which has finance leases inside it; operating leases are a separate line. Nothing here is a valuation or a view.

Price, 17 September 2021 to 21 September 2026

Daily closes from CBOE delayed quotes, daily history, by CBOE, for splits; the last is 21 September 2026. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Drawn in your browser; the range and overlay you pick are remembered here only.

The public record on CAH

Filings22 in twelve months: 12 current reports (8-K), about 6 regulation fd disclosure; 4 results of operations; 3 material agreement; 3 officer or director change; 1 termination of a material agreement
Planned insider sales11 Form 144 notices in twelve months, $70.5 million; latest 19 August 2026
Options tapeput/call 0.28 by open interest on 23 September 2026; the straddle prices a 2.5% move to 25 September 2026
Holders11 of the followed funds hold it; largest Geode Capital Management; 6 Schedule 13D or 13G filings in twelve months
Insider trading35 sales and 0 purchases on Form 4 in twelve months
Congress0 House trades disclosed in six months
Short interest6.7 million shares short, 4.44 days to cover at 31 August 2026
Documentsthe 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Quarterly results, the last 12 quarters

Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026
Revenue50,48753,45354,76357,44554,91159,70852,27755,26454,87860,15964,00965,627
Cost of revenue48,70251,62652,99555,59952,96457,85550,37553,32352,75557,95761,69063,230
Gross profit1,7851,8271,7681,8461,9471,8531,9021,9412,1232,2022,3192,397
Gross margin4%3%3%3%4%3%4%4%4%4%4%4%
SG&A1,1791,2671,1971,2831,2821,2381,2771,3061,3151,4841,4611,504
Operating income572137-14.0482367408568549730428668707
Operating margin1%0%-0%1%1%1%1%1%1%1%1%1%
Interest expense28.015.014.08.033.0-4.032.035.074.074.080.088.0
Pre-tax income544121-26.0490341396541511665384598630
Tax rate36%155%n/a28%24%41%23%22%24%37%24%25%
Net income345-64.05.0353258236416400506239450467
Net margin1%-0%0%1%0%0%1%1%1%0%1%1%
Diluted EPS$1.41-$0.51$0.02$1.50$1.07$0.86$1.70n/an/an/a$1.88n/a
Operating cash flow1,3618585451,189-49.02,077-1,647-4002,9171,527973686
Capital expenditure10921792.011411219390.099.0126232108131
Free cash flow1,2526414531,075-1611,884-1,737-4992,7911,295865555
Buybacks2505005002500.00.037515.03750.0375383
Dividends paid128126131124122122128122124120129122
Shares outstanding255m251m246m243m244m244m242m242m239m239m238m235m
Filing10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Profit and loss, 12 fiscal years and the trailing twelve months

FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022 FY2023 FY2024FY2025FY2026TTM
Revenue102,531121,546129,976136,809145,534152,922162,467181,364205,012226,827222,578254,248244,673
Cost of revenue96,819115,003123,432129,628138,700146,054155,689174,819198,123219,413214,410244,474235,632
Gross profit5,7126,5436,5447,1816,8346,8686,7786,4846,8747,4148,1689,7749,041
Gross margin5.6%5.4%5.0%5.2%4.7%4.5%4.2%3.6%3.4%3.3%3.7%3.8%3.7%
Selling, general and administrative3,2403,6483,7754,5964,4804,5724,5334,5124,8005,0005,3826,1325,764
Operating income2,1612,4592,1201262,060-4,098472-6077521,2432,2752,6132,533
Operating margin2.1%2.0%1.6%0.1%1.4%-2.7%0.3%-0.3%0.4%0.5%1.0%1.0%1.0%
Interest expense14117820132929423818014784.051.0215348316
Pre-tax income1,9672,2761,924-2281,751-3,772323-7846631,2012,1012,1742,277
Income tax755845630-487386-79.0-289153332348532469601
Effective tax rate38.4%37.1%32.7%n/a22.0%n/a-89.5%n/a50.1%29.0%25.3%21.6%26.4%
Net income1,2151,4271,2882561,363-3,696611-9383308521,5611,7141,662
Net margin1.2%1.2%1.0%0.2%0.9%-2.4%0.4%-0.5%0.2%0.4%0.7%0.7%0.7%
Diluted EPS$3.62$4.32$4.03$0.81$4.53-$12.61$2.08-$3.35$1.00$3.45$6.45$7.23n/a
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

Income statement lines from each year's 10-K, the year linked to its filing; TTM is the sum of the last four quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Cash flow and capital returned

FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022 FY2023 FY2024FY2025FY2026TTM
Operating cash flow2,5402,9711,1842,7682,7221,9602,4293,1752,8393,7622,3975,1746,103
Capital expenditure300465387384328375400387481511547649597
Free cash flow2,2402,5067972,3842,3941,5852,0292,7882,3583,2511,8504,5255,506
Free cash flow margin2.2%2.1%0.6%1.7%1.6%1.0%1.2%1.5%1.2%1.4%0.8%1.8%2.3%
Depreciation and amortisation4516417171,0321,000913783692692710790956883
Share-based compensation11011196.085.082.090.089.081.096.0121244367309
Buybacks1,0366516005506003502001,0002,0007507651,3581,133
Dividends paid460512577581577569573559525499494491495
Dividend per share$1.37$1.55$1.80$1.85$1.91$1.92$1.94$1.96$1.98$2.00$2.02$2.04n/a
Diluted shares, weighted335m330m320m315m301m293m294m279m262m247m242m237m237m
Shares outstanding at period endn/an/an/an/an/an/an/an/an/an/an/an/a235m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

Buybacks and dividends are the cash paid in the year, from the cash flow statement; the dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet at year end

FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022 FY2023 FY2024FY2025FY2026TTM
Total assets30,14234,12240,11239,95140,96340,76644,45343,87843,41745,12153,12257,29958,083
Cash and equivalents4,6162,3566,8791,7632,5312,7713,4074,7174,0765,1333,8744,8562,777
Receivables6,5237,4058,0487,8008,4488,2649,10310,56111,10812,08413,24213,81513,662
Inventory9,21110,61511,30112,30812,82213,19814,59415,63616,11914,95716,83117,29720,116
Goodwill5,0707,1677,2218,3168,3788,3577,9895,8554,6094,7259,69111,44211,609
Total debt, as filedn/an/an/an/an/a6,8006,2005,3004,7005,1008,527n/an/a
Long-term debt including finance leases5,2114,9529,0688,0127,5796,7655,3654,7353,9094,6587,9777,0048,347
Operating lease liabilitiesn/an/an/an/an/a341374388375400654861n/a
Finance lease liabilitiesn/an/an/an/an/a25.045.049.059.075.0157140n/a
Shareholders' equity6,2566,5546,8086,0596,3281,7891,791-709-2,958-3,213-2,781-2,883-2,884
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

At the fiscal year end; the TTM column is the latest quarter end. A line the company does not tag under the usual name is left out.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded7.7%9.4%7.4%10.1%
Profit growth, compounded1.8%22.9%73.2%26.9%
Return on equity, averagen/an/an/an/a

Compounded growth is the latest fiscal year over the year that many years earlier, annualised; the TTM column is the last four quarters over the four before. Return on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Peers: Wholesale-Drugs, Proprietaries & Druggists' Sundries

CompanyMarket capP/EROEOp. marginSales growth
TTM
Debt to equityDiv. yield
Mckesson Corp. MCK$103.4 billion23.78n/a1.6%8.8%n/a0.4%
Cencora, Inc. COR$60.4 billion23.5086.0%0.9%5.1%3.840.7%
Cardinal Health Inc. CAH$53.1 billion32.54n/a1.0%10.1%n/a0.9%

The names on this site in the same industry (the SEC's SIC description), by market capitalisation. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close.

Filings

FilingPeriodFiledWhere
10-K30 June 202611 August 2026EDGAR
10-Q31 March 202630 April 2026EDGAR
10-Q31 December 20255 February 2026EDGAR
10-Q30 September 202530 October 2025EDGAR
10-K30 June 202512 August 2025EDGAR
10-Q31 March 20251 May 2025EDGAR
10-Q31 December 202430 January 2025EDGAR
10-Q30 September 20241 November 2024EDGAR
10-K30 June 202414 August 2024EDGAR
10-Q31 March 20242 May 2024EDGAR

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install